CD274 and neoplasm: Interruption of the NKG2A receptor with its ligand human leukocyte antigen (HLA)‐E improved antitumor responses of PD‐L1 blockade therapy and therapeutic peptide vaccination in more than five different mouse tumor models.15, 18